Insider · CIK 0001846282
David Francisco
Files at ORGO (Organogenesis Holdings Inc.). First filing -, latest -.
In brief
David Francisco files SEC Form 4 as CFO at ORGO (Organogenesis Holdings Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; David Francisco has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | ORGO Organogenesis Holdings Inc. | AGrant or award Class A Common Stock | +44,040 | $0.00 | $0 | 745,999 | Mar 3, 2026 |
| Feb 18, 2026 | ORGO Organogenesis Holdings Inc. | FTax withholding Class A Common Stock | -14,687 | $3.84 | $56k | 731,312 | Mar 3, 2026 |
| Feb 18, 2026 | ORGO Organogenesis Holdings Inc. | AGrant or award Class A Common Stock | +195,312 | $0.00 | $0 | 701,959 | Feb 20, 2026 |
| Feb 18, 2026 | ORGO Organogenesis Holdings Inc. | AGrant or award Class A Common Stock | +43,602 | $0.00 | $0 | 745,561 | Feb 20, 2026 |
| Feb 18, 2026 | ORGO Organogenesis Holdings Inc. | FTax withholding Class A Common Stock | -14,541 | $3.84 | $56k | 731,020 | Feb 20, 2026 |
| Feb 18, 2026 | ORGO Organogenesis Holdings Inc. | AGrant or award Stock Option (Right to Buy)derivative | +111,358 | $0.00 | $0 | 111,358 | Feb 20, 2026 |
| Feb 15, 2026 | ORGO Organogenesis Holdings Inc. | FTax withholding Class A Common Stock | -3,898 | $3.73 | $15k | 555,197 | Feb 18, 2026 |
| Feb 15, 2026 | ORGO Organogenesis Holdings Inc. | FTax withholding Class A Common Stock | -21,412 | $3.73 | $80k | 533,785 | Feb 18, 2026 |
| Feb 15, 2026 | ORGO Organogenesis Holdings Inc. | FTax withholding Class A Common Stock | -13,369 | $3.73 | $50k | 520,416 | Feb 18, 2026 |
| Feb 15, 2026 | ORGO Organogenesis Holdings Inc. | FTax withholding Class A Common Stock | -13,769 | $3.73 | $51k | 506,647 | Feb 18, 2026 |
| Feb 19, 2025 | ORGO Organogenesis Holdings Inc. | AGrant or award Class A Common Stock | +165,156 | $0.00 | $0 | 559,095 | Feb 21, 2025 |
| Feb 19, 2025 | ORGO Organogenesis Holdings Inc. | AGrant or award Stock Option (Right to Buy)derivative | +170,841 | $0.00 | $0 | 170,841 | Feb 21, 2025 |
| Feb 15, 2025 | ORGO Organogenesis Holdings Inc. | FTax withholding Class A Common Stock | -11,765 | $3.70 | $44k | 417,231 | Feb 19, 2025 |
| Feb 15, 2025 | ORGO Organogenesis Holdings Inc. | FTax withholding Class A Common Stock | -19,528 | $3.70 | $72k | 397,703 | Feb 19, 2025 |
| Feb 15, 2025 | ORGO Organogenesis Holdings Inc. | FTax withholding Class A Common Stock | -2,960 | $3.70 | $11k | 394,743 | Feb 19, 2025 |
| Feb 16, 2025 | ORGO Organogenesis Holdings Inc. | FTax withholding Class A Common Stock | -804 | $3.70 | $2,975 | 393,939 | Feb 19, 2025 |
Questions about David Francisco
Answered from the filings on this page, as of the latest one.
Is David Francisco buying or selling?
David Francisco has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did David Francisco's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David Francisco has 0.
Where does David Francisco file Form 4?
David Francisco has filed Form 4 at ORGO (Organogenesis Holdings Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.